Liraglutide

Liraglutide is a GLP-1 receptor agonist FDA-approved for weight management (Saxenda, 3mg daily) and type 2 diabetes (Victoza, 1.8mg daily). As a daily injection, it offers an alternative to weekly semaglutide for patients who prefer more frequent but lower-peak dosing, or who experience side effects with weekly formulations. Compounded versions are available.

Category
Weight Loss & Metabolic
Demand
High
Route
Subcutaneous injection (daily)
FDA status
FDA-approved (Saxenda/Victoza); compounding eligibility tied to shortage status. Verify current classification before prescribing
Also known as
SaxendaVictoza

How Liraglutide Works

Liraglutide is a GLP-1 analog with 97% homology to native GLP-1, modified with a C-16 fatty acid chain that enables albumin binding and extends half-life to approximately 13 hours (compared to 2 minutes for native GLP-1) [4]. It activates hypothalamic GLP-1 receptors to reduce appetite, stimulates glucose-dependent insulin secretion from pancreatic beta cells, and delays gastric emptying [1]. The daily dosing produces less pronounced peak-trough fluctuations compared to weekly formulations.

Clinical Evidence

The SCALE Obesity and Prediabetes trial demonstrated 8.0% mean body weight reduction at 56 weeks with liraglutide 3mg daily versus 2.6% with placebo [1]. The LEADER cardiovascular outcomes trial showed a 13% reduction in major adverse cardiovascular events in patients with type 2 diabetes [3]. FDA approved liraglutide for chronic weight management (Saxenda) in December 2014 [2], making it the first GLP-1 agonist approved for obesity. Long-term safety data exceeds 10 years of clinical experience, providing the most extensive safety profile among GLP-1 weight loss medications [4].

Clinical Uses

  • Chronic weight management (FDA-approved as Saxenda at 3mg daily)
  • Type 2 diabetes glycemic control (FDA-approved as Victoza)
  • Cardiovascular risk reduction in patients with established CVD
  • Appetite regulation and caloric intake reduction

Patient Selection and Screening

Good candidates include patients who experience intolerable side effects with weekly GLP-1 formulations (daily dosing allows faster dose adjustment), those who prefer a more gradual pharmacokinetic profile, or patients new to GLP-1 therapy who want a gentler introduction [4]. Also appropriate for adolescents aged 12+ with obesity (FDA-approved indication) [2]. Screen for personal or family history of medullary thyroid carcinoma or MEN 2 syndrome. Evaluate for pancreatitis history and gallbladder disease before initiation [3].

Dosing and Administration

Weight management titration per FDA labeling: 0.6mg daily for week 1, 1.2mg for week 2, 1.8mg for week 3, 2.4mg for week 4, 3.0mg daily maintenance from week 5 [4]. If patients cannot tolerate dose escalation, hold at current dose for an additional week before advancing. Discontinue if patient has not achieved at least 4% weight loss by 16 weeks at full dose [2]. For diabetes (Victoza), target 1.2-1.8mg daily. Dosing flexibility is a key advantage; reduce dose immediately if GI intolerance develops.

Route
Subcutaneous injection (daily)
Protocol notes
Administered via daily subcutaneous injection with dose titration over 4-5 weeks. Weight loss protocol: start 0.6mg daily, increase by 0.6mg weekly to target dose of 3mg daily. Diabetes protocol targets 1.2-1.8mg daily.

Safety and Monitoring

Potential side effects

  • Nausea (39% incidence; most common during titration, improves with time)
  • Diarrhea, constipation, and vomiting (common during dose escalation)
  • Headache and dizziness (mild, typically transient)
  • Pancreatitis (rare but serious; discontinue and do not restart if confirmed)
  • Gallbladder events including cholelithiasis (associated with rapid weight loss)

Clinical considerations

  • Daily injection (vs weekly for semaglutide/tirzepatide) may reduce patient adherence but allows faster dose adjustment
  • GI side effects common during titration (nausea, vomiting, diarrhea); slow titration improves tolerability
  • Same class contraindications: personal/family history of medullary thyroid carcinoma, MEN 2 syndrome
  • Monitor for pancreatitis symptoms and gallbladder disease
  • Compounding eligibility depends on FDA shortage status; verify current availability

Practice Economics

Liraglutide programs are positioned as an accessible GLP-1 option with lower monthly costs than semaglutide or tirzepatide, typically $200-400 per month for compounded formulations. The extensive safety record [3] and FDA-approved adolescent indication [2] create differentiation opportunities. Practices can offer liraglutide as a first-line option or as a step-down for patients completing intensive semaglutide programs.

FDA Category Status

FDA-approved (Saxenda/Victoza); compounding eligibility tied to shortage status. Verify current classification before prescribing

FDA bulk drug substance category determines compounding eligibility. Category designations are subject to change; always verify current status before prescribing.

Frequently Asked Questions

When should liraglutide be chosen over semaglutide?

Liraglutide may be preferred when patients experience intolerable side effects with weekly semaglutide (the daily dosing allows faster dose reduction), when a more gradual GLP-1 effect is desired, when weekly formulations are unavailable, or as a stepping stone before transitioning to weekly agents. Some patients also prefer the perceived control of daily dosing.

How does liraglutide weight loss compare to semaglutide?

Clinical trials show semaglutide 2.4mg weekly produces greater weight loss (approximately 15% body weight) than liraglutide 3mg daily (approximately 8% body weight). However, liraglutide has a longer clinical track record, more safety data, and some patients achieve adequate results without needing the more potent weekly agents.

What is the transition protocol from liraglutide to semaglutide?

There is no established direct conversion. Common clinical practice is to discontinue liraglutide, wait 24-48 hours (given liraglutide's 13-hour half-life), then initiate semaglutide at the lowest dose (0.25mg weekly) with standard titration. Do not overlap the two GLP-1 agonists. Monitor for GI tolerability during the transition.

References

  1. Pi-Sunyer et al. - Liraglutide 3.0mg for Weight Management (SCALE Obesity, NEJM 2015)
  2. FDA Approval of Saxenda (liraglutide 3mg) for Chronic Weight Management
  3. Marso et al. - Liraglutide and Cardiovascular Outcomes (LEADER Trial, NEJM 2016)
  4. Saxenda (liraglutide) Prescribing Information

Disclaimer: This information is intended for licensed healthcare providers only and does not constitute medical, legal, or regulatory advice. Clinical decisions should be based on your professional judgment, current evidence, and applicable regulations. Always verify FDA category status and compounding eligibility before prescribing.

Launch a Peptide Program With Karpa

Karpa handles intake, licensed prescribing, and direct-to-patient pharmacy fulfillment across all 50 states. No medical license required.

Explore peptide programs